Bosentan alleviates the pro-fibrotic phenotype of lung scleroderma fibroblasts: Implications for treatment of scleroderma.
Auteurs principaux: | Leask, A, Xu, S, Renzoni, E, Bou-Gharios, G, du Bois, R, Abraham, D, Black, C |
---|---|
Format: | Conference item |
Publié: |
2005
|
Documents similaires
-
Bosentan attenuates the profibrotic gene expression profile of lung fibroblasts in scleroderma
par: Shiwen, X, et autres
Publié: (2006) -
Effects of bosentan on collagen type I synthesis on in vitro culture of scleroderma skin fibroblasts
par: S. Soldano, et autres
Publié: (2011-01-01) -
Successful Treatment with Bosentan of Lower Extremity Ulcers in a Scleroderma Patient
par: Alix Naert, et autres
Publié: (2013-01-01) -
CTGF overexpressing mice: a model for human scleroderma
par: Sonnylal, S, et autres
Publié: (2006) -
Bosentan Does Not Affect Renal Resistive Index in Scleroderma/Systemic Sclerosis Patients
par: Emma Di Poi, et autres
Publié: (2023-11-01)